- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Long-Term PPI Use Linked to Modest Bone Mineral Density Reduction: Study

Researchers have discovered in a new research that Proton pump inhibitor (PPI) use for 6 months or longer was associated with a modest decrease in bone mineral density (BMD), particularly at the hip and femoral neck, potentially increasing fracture risk. Clinicians should prescribe the lowest effective dose for the shortest duration and monitor bone mineral density in high-risk patients on long-term PPI therapy.
Proton pump inhibitors (PPIs) are often prescribed for acid-related disorders, but while chronic use may harm bone health, a clear link to changes in bone mineral density (BMD) remains unestablished.
Therefore, this systematic review aims to evaluate the association between prolonged PPI therapy and changes in bone mineral density across skeletal sites. Following a comprehensive search of PubMed/MEDLINE, Cochrane CENTRAL, Web of Science, and Scopus databases identified original research studies assessing changes in bone mineral density among adults (≥18 years) using PPIs for ≥6 months.
Two reviewers independently extracted the data for qualitative data synthesis. Risk-of-bias was assessed using the ROBINS-E tool. A total of 14 studies (11 cohort, two cross-sectional, one case-control), with participants ranging from 40 to >6,000, were included. Most studies (13 out of 14; 92.9%) assessed bone mineral density changes in the hip, femoral neck, and lumbar spine. Ten studies (71%) found significant bone mineral density reductions among PPI users, particularly at the hip and femoral neck, and also in the mandible.
Findings for lumbar spine bone mineral density were inconsistent. Longer PPI therapy (>1 year) and higher doses were associated with greater bone mineral density reductions. Esomeprazole and lansoprazole were linked to more significant bone mineral density loss than omeprazole, with older adults, males, and postmenopausal women being more affected. Proposed mechanisms include impaired calcium absorption, osteoclast-mediated trabecular bone reduction, altered plasma metabolites, and inhibition of bone-specific enzymes.
Prolonged PPI use ≥6 months is linked with a modest overall reduction in bone mineral density, especially in the hip and femoral neck, which may contribute to fracture risk. Clinicians should use the lowest effective dose and duration, and regularly monitor bone mineral density in high-risk patients using PPIs.
Reference:
Sundar C, Devang Divakar D, Kumar S, et al. (April 09, 2026) Impact of Proton Pump Inhibitor Therapy on Bone Mineral Density: An Updated Systematic Review. Cureus 18(4): e106698. doi:10.7759/cureus.106698
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

